U.S. Food and Drug Administration Center for Drug Evaluation and ResearchSkip navigation

CDER - Center for Drug Evaluation and Research Logo

Office of Generic Drugs

CDER Home Site Information Comments and Feedback What's New CDER Navigation Bar

Reference Listed Drug Labeling Approved in February 2001

Click on appropriate hyperlink below to view available source document in PDF format.

Approval Date

Product Name

    Established Name

NDA No.

Supp.No.

Feb 2

IMITREX

letter

label

sumatriptan succinate injection

20-080

S-027

Feb 5

CHIBROXIN

letter

label

norfloxacin ophthalmic solution

19-757

S-010

TOPROL-XL

letter

label

metoprolol succinate tablets

19-962

S-013

Feb 6

LEVATOL

letter

label

penbutolol sulfate tablets

18-976

S-009

MERREM I.V.

letter

label

meropenem for injection

50-706

S-007

SUPRAX

letter

label

cefixime oral suspension

50-622

S-014

VANCOCIN HCL

letter

label

vancomycin hydrochloride capsules

50-606

S-014

ZYVOX

letter

label

linezolid tablets

linezolid injection

linezolid for oral suspension

21-130

21-131

21-132

S-001

S-001

S-001

Feb 8

AVANDIA

letter

label

rosiglitazone maleate tablets

21-071

S-006

GLUCOPHAGE

letter

label

metformin hydrochloride tablets

20-357

S-022

Feb 9

PEPCID

PEPCID RPD

letter

label

famotidine tablets

famotidine injection

famotidine oral suspension

famotidine injection

famotidine orally disintegrating tablets

19-462

19-510

19-527

20-249

20-752

S-029

S-027

S-023

S-010

S-004

IMITREX

letter

label

sumatriptan succinate tablets

20-132

S-010

Feb 12

HUMATROPE

letter

label

somatropin [rDNA origin] for injection

19-640

S-026

MS CONTIN

letter

label

morphine sulfate extended-release tablet

19-516

S-015

PROTROPIN

letter

label

somatrem for injection

19-107

S-048

Feb 13

OPTICROM

letter

label

cromolyn sodium ophthalmic solution

18-155

S-022

VASOTEC

letter

label

enalapril maleate tablets

18-998

S-059

VENOFER

letter

label

iron sucrose injection

21-135

S-001

Feb 14

KETALAR

letter

label

ketamine hydrochloride injection

16-812

S-026

Feb 15

DELSYM

letter

label

dextromethorphan polistirex suspension

18-658

S-014

PAXIL

letter

label

paroxetine hydrochloride tablets

paroxetine hydrochloride oral suspension

20-031

20-710

S-031

S-009

Feb 16

MERIDIA

letter

label

sibutramine HCl monohydrate capsules

20-632

S-011

MONOPRIL-HCT

letter

label

fosinopril sodium/hydrochlorothiazide tablets

20-286

S-004

Feb 20

DROXIA

HYDREA

letter

label

hydroxyurea capsules

16-295

S-035

MIVACRON

letter

label

mivacurium chloride injection

20-098

S-012

Feb 22

DIMETANE-DX

letter

label

brompheniramine maleate/pseudoephedrine HCl/dextromethorphan HBr

19-279

S-010

ZOLOFT

letter

label

sertraline hydrochloride tablets

sertraline hydrochloride oral concentrate

19-839

20-990

S-037

S-005

SONATA

letter

label

zaleplon capsules

20-859

S-001

Feb 23

DIPRIVAN

letter

label

propofol injectable emulsion

19-627

S-035

DYAZIDE

letter

label

hydrochlorothiazide/triamterene capsules

16-042

S-069

LAMICTAL

LAMICTAL CD

letter

label

lamotrigine tablets

lamotrigine chewable dispersible tablets

20-241

20-764

S-015

S-008

MYLOTARG

letter

label

gemtuzumab ozogamicin for injection

21-174

S-002

PHENERGAN VC

letter

label

promethazine HCl/codeine phosphate syrup

08-604

S-026

PHENERGAN VC/CODEINE

PHENERGAN/CODEINE

letter

label

promethazine HCl/phenylephrine HCl/codeine phosphate syrup

promethazine HCl/codeine phosphate syrup

08-306

S-029

PHENERGAN DM

letter

label

promethazine HCl/dextromethorphan HBr syrup

11-265

S-027

REBETOL

letter

label

interferon alfa-2b,ribavirin

20-903

S-005

Feb 28

COPAXONE

letter

label

glatiramer acetate for injection

20-622

S-020

GLUCOVANCE

letter

label

glyburide/metformin HCl tablets

21-178

S-002

ZITHROMAX

letter

label

azithromycin for injection

50-733

S-005

FDA/Center for Drug Evaluation and Research
Last Updated: October 02, 2001
Originator: OTCOM/DLIS
HTML by JFG